Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Vxbiosciences Inc. is currently navigating 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners but are both contained within 1 distinct art unit, showing a centralized administrative review for the company's active matters. This arrangement suggests that the company's current patent efforts are focused on a specific biotechnology niche. The presence of 2 pending office actions indicates a steady level of prosecution activity. Having 2 distinct examiners within 1 distinct art unit means that while different people are reviewing the cases, they are likely following the same departmental guidelines.
STEPHANIE LAUREN SULLIVAN is the busiest examiner for the portfolio, managing 1 busiest examiner pending action. This examiner is one of the 2 distinct individuals currently reviewing the company's applications. The concentration of 2 distinct examiners in 1 distinct art unit indicates that the pending cases are being evaluated within the same technical division. This 1 distinct art unit serves as the primary administrative hub for the company's active Biotechnology & Pharmaceuticals filings. Practitioners should focus on the 1 busiest examiner pending action while ensuring consistency across the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SULLIVAN, STEPHANIE LAUREN | 1 | 57.1% | +38.1% |
| SHIN, DANA H | 1 | 26.9% | +26.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17920682 | THERAPEUTIC INTERFERING PARTICLES FOR CORONA VIRUS | SHIN, DANA H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18553900 | THERAPEUTIC INTERFERING PARTICLES FOR CORONA VIRUS | SULLIVAN, STEPHANIE LAUREN | — |
| 17920682 | THERAPEUTIC INTERFERING PARTICLES FOR CORONA VIRUS | SHIN, DANA H | — |
| Art Unit | Apps |
|---|---|
| 1635 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18553900 | THERAPEUTIC INTERFERING PARTICLES FOR CORONA VIRUS | SULLIVAN, STEPHANIE LAUREN | 1635 | §102§103§112DP | Non-Final OA | — | Pending | Oct 04, 2023 |
| 17920682 | THERAPEUTIC INTERFERING PARTICLES FOR CORONA VIRUS | SHIN, DANA H | 1635 | §102§103§112DP | Non-Final OA | — | Pending | Oct 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVxbiosciences Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Stephanie Lauren Sullivan has the most, with 1 of Vxbiosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
